Back to Search Start Over

Objectives and design of the hemodialysis fistula maturation study.

Authors :
Dember LM
Imrey PB
Beck GJ
Cheung AK
Himmelfarb J
Huber TS
Kusek JW
Roy-Chaudhury P
Vazquez MA
Alpers CE
Robbin ML
Vita JA
Greene T
Gassman JJ
Feldman HI
Source :
American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2014 Jan; Vol. 63 (1), pp. 104-12. Date of Electronic Publication: 2013 Aug 28.
Publication Year :
2014

Abstract

Background: A large proportion of newly created arteriovenous fistulas cannot be used for dialysis because they fail to mature adequately to support the hemodialysis blood circuit. The Hemodialysis Fistula Maturation (HFM) Study was designed to elucidate clinical and biological factors associated with fistula maturation outcomes.<br />Study Design: Multicenter prospective cohort study.<br />Setting & Participants: Approximately 600 patients undergoing creation of a new hemodialysis fistula will be enrolled at 7 centers in the United States and followed up for as long as 4 years.<br />Predictors: Clinical, anatomical, biological, and process-of-care attributes identified pre-, intra-, or postoperatively.<br />Outcomes: The primary outcome is unassisted clinical maturation, defined as successful use of the fistula for dialysis for 4 weeks without maturation-enhancing procedures. Secondary outcomes include assisted clinical maturation, ultrasound-based anatomical maturation, fistula procedures, fistula abandonment, and central venous catheter use.<br />Measurements: Preoperative ultrasound arterial and venous mapping, flow-mediated and nitroglycerin-mediated brachial artery dilation, arterial pulse wave velocity, and venous distensibility; intraoperative vein tissue collection for histopathologic and molecular analyses; postoperative ultrasounds at 1 day, 2 weeks, 6 weeks, and prior to fistula intervention and initial cannulation.<br />Results: Assuming complete data, no covariate adjustment, and unassisted clinical maturation of 50%, there will be 80% power to detect ORs of 1.83 and 1.61 for dichotomous predictor variables with exposure prevalences of 20% and 50%, respectively.<br />Limitations: Exclusion of 2-stage transposition fistulas limits generalizability. The requirement for study visits may result in a cohort that is healthier than the overall population of patients undergoing fistula creation.<br />Conclusions: The HFM Study will be of sufficient size and scope to: (1) evaluate a broad range of mechanistic hypotheses, (2) identify clinical practices associated with maturation outcomes, (3) assess the predictive utility of early indicators of fistula outcome, and (4) establish targets for novel therapeutic interventions to improve fistula maturation.<br /> (Copyright © 2013 National Kidney Foundation, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1523-6838
Volume :
63
Issue :
1
Database :
MEDLINE
Journal :
American journal of kidney diseases : the official journal of the National Kidney Foundation
Publication Type :
Academic Journal
Accession number :
23992885
Full Text :
https://doi.org/10.1053/j.ajkd.2013.06.024